Welcome to our dedicated page for Envista Holdings SEC filings (Ticker: NVST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Envista Holdings Corporation filings document formal disclosures for a Delaware dental products issuer with common stock listed under NVST. Recent Form 8-K reports furnish quarterly financial results under Item 2.02, Regulation FD materials for earnings presentations, and corporate disclosures such as sustainability-report announcements.
The company's proxy materials cover board governance, executive compensation, equity awards and shareholder voting matters. Other material-event filings document director changes and related governance updates, while the filing record also identifies the company's Exchange Act reporting framework, capital-stock context and furnished status of investor materials.
Envista Holdings Corp (NVST) reported an insider transaction by Veronica Acurio, President, Orthodontics. On August 25, 2026, 7,710 shares of common stock were withheld at $27.47 per share to satisfy tax withholding obligations on vesting stock-settled Restricted Stock Units. After this tax-withholding disposition, Acurio directly holds 48,806 shares of Envista common stock.
Envista Holdings Corp (NVST) reported an insider equity event involving President, Diagnostics Robert Befidi. On 2026-08-25, 5,147 shares of common stock were withheld at $27.47 per share to satisfy tax withholding obligations upon the vesting of stock-settled Restricted Stock Units. After this tax-withholding disposition, Befidi directly holds 45,785 shares of Envista common stock.
Envista Holdings Corp (NVST) reported an insider equity transaction by Chief Financial Officer Eric D. Hammestax withholding obligations related to the vesting of stock-settled Restricted Stock Units. After this withholding transaction, Hammes directly holds 99,913 shares of Envista common stock.
Envista Holdings Corp (NVST) reported an insider equity-related transaction by Stefan Nilsson, President, Nobel Biocare. On 2026-08-25, 804 shares of common stock were withheld by the company to satisfy tax withholding obligations upon the vesting of stock-settled Restricted Stock Units. Following this non-market, tax-related disposition, Nilsson held 61,560 shares of Envista common stock directly.
Envista Holdings Corp (NVST) reported an insider transaction by Mischa Reis, SVP, Strategy & Business Development. On 2026-08-20, Reis sold 8,000 shares of common stock at $27.50 per share in an open market or private transaction under a previously adopted Rule 10b5-1 trading plan, and held 27,321 shares directly after the sale.
Envista Holdings Corp (NVST) reported that Chief Executive Officer Paul A. Keel received equity awards on 2026-08-18. He was granted 179,730 Restricted Stock Units that vest ratably over four years, each converting 1-for-1 into common stock, increasing his direct common stock holdings to 551,304 shares. He also received 159,900 Performance Share Units tied to performance over four years, with a payout range of 75%–125% of the target amount based on achievement of specified performance measures.
Envista Holdings Corp (symbol: NVST) is the issuer of record for a Form 4 filing submitted to the SEC.
Envista Holdings Corp (NVST) received a notice under Rule 144 that officer Mischa Reis, through Fidelity Brokerage Services LLC, may sell 8,000 shares of Envista common stock. The planned sale has an indicated aggregate market value of $220,000.00 and is to be executed on the NYSE on or after August 20, 2026.
The shares were acquired over time via multiple restricted stock vesting events between February 24, 2020 and February 25, 2025 as compensation from the issuer. No Rule 144 sales by this person are listed for the prior three months.
Envista Holdings Corporation (NVST) reported board-approved leadership and compensation changes for its top executives. Paul Keel, President and Chief Executive Officer, will become Chair of the Board effective August 19, 2026, succeeding director Scott Huennekens, who will continue as a director and serve as Lead Independent Director.
On August 17, 2026, the Compensation Committee increased Mr. Keel’s annual base salary by $200,000, from $1.1 million to $1.3 million, effective August 24, 2026, and approved a special one-time equity award of $10 million, split equally between time-based RSUs and performance-based PSUs. Both awards vest over a four‑year period, with PSUs tied to Envista’s four‑year total stockholder return relative to the S&P 400 Health Care Sector Index and subject to forfeiture on most terminations except death, early or normal retirement, or certain change-in-control related terminations. The Committee also granted Chief Financial Officer Eric Hammes a one-time PSU award valued at $1.5 million with the same four‑year TSR performance condition.
Envista Holdings Corp’s CAO Thomas Coree K. reports his initial beneficial ownership of company equity. The filing lists several employee stock options on common stock, including options over 7,730 shares at $22.65 expiring on February 25, 2034; 8,480 shares at $20.66 expiring on February 25, 2035; 6,010 shares at $29.59 expiring on February 25, 2036; and 4,710 shares at $38.25 expiring on February 25, 2033. It also discloses multiple tranches of restricted stock units scheduled to vest between August 25, 2026 and November 25, 2028, such as 514 RSUs vesting on August 25, 2026 and 5,940 RSUs vesting on November 25, 2028, all subject to continued service. In addition, Coree has 1,627 notional phantom shares tied to Envista stock through deferred contribution and excess contribution programs.